CAY10499
Based on 1 publication(s) in Google Scholar
CAY10499 (MAGL-IN-5) is a non-selective lipase inhibitor with IC50 values of 144 nM and 14 nM for monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), respectively. Additionally, CAY10499 exhibits anti-inflammatory and antiviral activities.
For research use only. We do not sell to patients.
- Purity: 99.58%
- CAS No.: 359714-55-9
- Formula: C18H17N3O5
- Molecular Weight:355.34
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) CAY10499
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Caov-3 cell line | IC50 |
77 μM
Compound: CAY10499
|
Antiproliferative activity against human Caov3 cells after 96 hrs
Antiproliferative activity against human Caov3 cells after 96 hrs
|
[PMID: 29309142] |
| Caov-3 cell line | IC50 |
83.1 μM
Compound: 2; CAY10499
|
Antiproliferative activity against human Caov-3 cells assessed as reduction in cell viability incubated for 96 hrs by Cell-titer-Glo luminescent cell viability assay
Antiproliferative activity against human Caov-3 cells assessed as reduction in cell viability incubated for 96 hrs by Cell-titer-Glo luminescent cell viability assay
|
[PMID: 27809504] |
| Caov-3 cell line | IC50 |
92 μM
Compound: 2; CAY10499
|
Growth inhibition of human Caov3 cells after 96 hrs by celltiter-glo assay
Growth inhibition of human Caov3 cells after 96 hrs by celltiter-glo assay
|
[PMID: 30715876] |
| Caov-3 cell line | IC50 |
92 μM
Compound: CAY10499; 2
|
Antiproliferative activity against human Caov3 cells measured after 96 hrs
Antiproliferative activity against human Caov3 cells measured after 96 hrs
|
[PMID: 30144699] |
| Caov-3 cell line | IC50 |
95 μM
Compound: CAY10499;2
|
Antiproliferative activity against human CAOV3 cells as reduction in cell growth measured after 96 hrs by Celltiter-glo luminescent assay
Antiproliferative activity against human CAOV3 cells as reduction in cell growth measured after 96 hrs by Celltiter-glo luminescent assay
|
[PMID: 33045662] |
| HCT-116 | IC50 |
38 μM
Compound: CAY10499;2
|
Antiproliferative activity against human HCT116 cells as reduction in cell growth measured after 96 hrs by Celltiter-glo luminescent assay
Antiproliferative activity against human HCT116 cells as reduction in cell growth measured after 96 hrs by Celltiter-glo luminescent assay
|
[PMID: 33045662] |
| HCT-116 | IC50 |
42 μM
Compound: 2; CAY10499
|
Growth inhibition of human HCT116 cells after 96 hrs by celltiter-glo assay
Growth inhibition of human HCT116 cells after 96 hrs by celltiter-glo assay
|
[PMID: 30715876] |
| HCT-116 | IC50 |
89 μM
Compound: CAY10499; 2
|
Antiproliferative activity against human HCT116 cells measured after 96 hrs
Antiproliferative activity against human HCT116 cells measured after 96 hrs
|
[PMID: 30144699] |
| MCF7 | IC50 |
4.2 μM
Compound: CAY10499
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs
|
[PMID: 24853323] |
| MDA-MB-231 | IC50 |
42 μM
Compound: CAY10499; 2
|
Antiproliferative activity against human MDA-MB-231 cells measured after 96 hrs
Antiproliferative activity against human MDA-MB-231 cells measured after 96 hrs
|
[PMID: 30144699] |
| MDA-MB-231 | IC50 |
46 μM
Compound: CAY10499
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 96 hrs
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 96 hrs
|
[PMID: 24853323] |
| MDA-MB-231 | IC50 |
83 μM
Compound: CAY10499;2
|
Antiproliferative activity against human MDA-MB-231 cells as reduction in cell growth measured after 96 hrs by Celltiter-glo luminescent assay
Antiproliferative activity against human MDA-MB-231 cells as reduction in cell growth measured after 96 hrs by Celltiter-glo luminescent assay
|
[PMID: 33045662] |
| MDA-MB-231 | IC50 |
89 μM
Compound: 2; CAY10499
|
Growth inhibition of human MDA-MB-231 cells after 96 hrs by celltiter-glo assay
Growth inhibition of human MDA-MB-231 cells after 96 hrs by celltiter-glo assay
|
[PMID: 30715876] |
| MRC5 | IC50 |
>100 μM
Compound: 2; CAY10499
|
Growth inhibition of human MRC5 cells after 96 hrs by celltiter-glo assay
Growth inhibition of human MRC5 cells after 96 hrs by celltiter-glo assay
|
[PMID: 30715876] |
| MRC5 | IC50 |
>100 μM
Compound: CAY10499
|
Antiproliferative activity against human MRC5 cells after 96 hrs
Antiproliferative activity against human MRC5 cells after 96 hrs
|
[PMID: 29309142] |
| MRC5 | IC50 |
>200 μM
Compound: 2; CAY10499
|
Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability incubated for 96 hrs by Cell-titer-Glo luminescent cell viability assay
Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability incubated for 96 hrs by Cell-titer-Glo luminescent cell viability assay
|
[PMID: 27809504] |
| OVCAR-3 | IC50 |
>79.8 μM
Compound: CAY10499
|
Cytotoxicity against human OVCAR3 cells assessed as growth inhibition after 96 hrs
Cytotoxicity against human OVCAR3 cells assessed as growth inhibition after 96 hrs
|
[PMID: 24853323] |
| OVCAR-3 | IC50 |
43 μM
Compound: CAY10499
|
Antiproliferative activity against human OVCAR3 cells after 96 hrs
Antiproliferative activity against human OVCAR3 cells after 96 hrs
|
[PMID: 29309142] |
| OVCAR-3 | IC50 |
45 μM
Compound: 2; CAY10499
|
Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 96 hrs by Cell-titer-Glo luminescent cell viability assay
Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 96 hrs by Cell-titer-Glo luminescent cell viability assay
|
[PMID: 27809504] |
| OVCAR-3 | IC50 |
50 μM
Compound: 2; CAY10499
|
Growth inhibition of human OVCAR3 cells after 96 hrs by celltiter-glo assay
Growth inhibition of human OVCAR3 cells after 96 hrs by celltiter-glo assay
|
[PMID: 30715876] |
| OVCAR-3 | IC50 |
50 μM
Compound: CAY10499; 2
|
Antiproliferative activity against human OVCAR3 cells measured after 96 hrs
Antiproliferative activity against human OVCAR3 cells measured after 96 hrs
|
[PMID: 30144699] |
| OVCAR-3 | IC50 |
53 μM
Compound: CAY10499;2
|
Antiproliferative activity against human OVCAR3 cells as reduction in cell growth measured after 96 hrs by Celltiter-glo luminescent assay
Antiproliferative activity against human OVCAR3 cells as reduction in cell growth measured after 96 hrs by Celltiter-glo luminescent assay
|
[PMID: 33045662] |
| SK-OV-3 | IC50 |
33 μM
Compound: CAY10499;2
|
Antiproliferative activity against human SKOV3 cells as reduction in cell growth measured after 96 hrs by Celltiter-glo luminescent assay
Antiproliferative activity against human SKOV3 cells as reduction in cell growth measured after 96 hrs by Celltiter-glo luminescent assay
|
[PMID: 33045662] |
| SK-OV-3 | IC50 |
34 μM
Compound: 2; CAY10499
|
Growth inhibition of human SKOV3 cells after 96 hrs by celltiter-glo assay
Growth inhibition of human SKOV3 cells after 96 hrs by celltiter-glo assay
|
[PMID: 30715876] |
| SK-OV-3 | IC50 |
34 μM
Compound: CAY10499; 2
|
Antiproliferative activity against human SKOV3 cells measured after 96 hrs
Antiproliferative activity against human SKOV3 cells measured after 96 hrs
|
[PMID: 30144699] |
CAY10499 (20 mg/L; 42-44 h) can inhibit the maturation of oocytes, increase the triglyceride content in mature oocytes, and reduce the mitochondrial membrane potential[1].
CAY10499 (20 μM; 12-18 h) exhibits antiviral and anti-inflammatory activities in SARS-CoV-2-infected Vero E6 cells and IAV-infected A549 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SARS-CoV-2-infected Vero E6 cells
-
Concentration:20 μM
-
Incubation Time:12 and 18 h
-
Result:Markedly reduced levels of TNF-α, IL-6, and MCP-1.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 359714-55-9
-
Appearance Solid
-
Molecular Weight 355.34
-
Formula C18H17N3O5
-
Color Off-white to yellow
-
SMILES
O=C(OCC1=CC=CC=C1)NC2=CC=C(N3C(OC(OC)=N3)=O)C=C2C
-
Synonyms
MAGL-IN-5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Phosphorylation of 17β-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice. [Abstract]2022 Nov 2;13(1):6577. PMID: 36323699
Solvent & Solubility
DMSO : ≥ 100 mg/mL (281.42 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.04 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhuan Q, et al. Cytoplasm lipids can be modulated through hormone-sensitive lipase and are related to mitochondrial function in porcine IVM oocytes. Reprod Fertil Dev. 2020 Apr;32(7):667-675. [Content Brief]
[2]. Baek YB, et al. Therapeutic strategy targeting host lipolysis limits infection by SARS-CoV-2 and influenza A virus. Signal Transduct Target Ther. 2022 Oct 17;7(1):367. [Content Brief]
[3]. Muccioli GG, et al. CAY10499, a novel monoglyceride lipase inhibitor evidenced by an expeditious MGL assay. Chembiochem. 2008 Nov 3;9(16):2704-10. [Content Brief]
[4]. Granchi C, et al. 4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors. J Enzyme Inhib Med Chem. 2016;31(1):137-46. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8142 mL | 14.0710 mL | 28.1421 mL | 70.3552 mL |
| 5 mM | 0.5628 mL | 2.8142 mL | 5.6284 mL | 14.0710 mL | |
| 10 mM | 0.2814 mL | 1.4071 mL | 2.8142 mL | 7.0355 mL | |
| 15 mM | 0.1876 mL | 0.9381 mL | 1.8761 mL | 4.6903 mL | |
| 20 mM | 0.1407 mL | 0.7036 mL | 1.4071 mL | 3.5178 mL | |
| 25 mM | 0.1126 mL | 0.5628 mL | 1.1257 mL | 2.8142 mL | |
| 30 mM | 0.0938 mL | 0.4690 mL | 0.9381 mL | 2.3452 mL | |
| 40 mM | 0.0704 mL | 0.3518 mL | 0.7036 mL | 1.7589 mL | |
| 50 mM | 0.0563 mL | 0.2814 mL | 0.5628 mL | 1.4071 mL | |
| 60 mM | 0.0469 mL | 0.2345 mL | 0.4690 mL | 1.1726 mL | |
| 80 mM | 0.0352 mL | 0.1759 mL | 0.3518 mL | 0.8794 mL | |
| 100 mM | 0.0281 mL | 0.1407 mL | 0.2814 mL | 0.7036 mL |